Prognostic role of E-cadherin in patients with advanced serous ovarian cancer

Purpose To analyse correlation between expression of E-cadherin and clinical and pathological features and overall survival in advanced-stage serous ovarian carcinoma. Methods The expression of E-cadherin was analysed immunohistochemically in formalin-fixed, paraffin-embedded samples from 54 patient...

Full description

Saved in:
Bibliographic Details
Published in:Archives of gynecology and obstetrics 2013-06, Vol.287 (6), p.1219-1224
Main Authors: Bačić, Boris, Haller, Herman, Mrklić, Ivana, Košta, Vana, Čarić, Ana, Tomić, Snježana
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - analysis
Cadherins - analysis
Endocrinology
Female
Gynecologic Oncology
Gynecology
Human Genetics
Humans
Immunohistochemistry
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Staging
Neoplasm, Residual - pathology
Neoplasms, Cystic, Mucinous, and Serous - chemistry
Neoplasms, Cystic, Mucinous, and Serous - mortality
Neoplasms, Cystic, Mucinous, and Serous - pathology
Obstetrics/Perinatology/Midwifery
Ovarian cancer
Ovarian Neoplasms - chemistry
Ovarian Neoplasms - mortality
Ovarian Neoplasms - pathology
Prognosis
Surgery
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To analyse correlation between expression of E-cadherin and clinical and pathological features and overall survival in advanced-stage serous ovarian carcinoma. Methods The expression of E-cadherin was analysed immunohistochemically in formalin-fixed, paraffin-embedded samples from 54 patients with advanced-stage serous ovarian cancer and related to clinicopathological characteristics and patients survival. The clinicopathological characteristics included the stage according to the International Federation of Gynecology and Obstetrics (FIGO), tumour differentiation, number of mitoses per 10 high-power fields (HPF), residual tumour size, and vascular invasion. Only patients with serous ovarian cancer FIGO stages III–IV were included. Overall survival (OS) was defined as time from surgery to the last follow-up date on 01.10.2010. OS was evaluated using Kaplan–Meier method, and log-rank test was used to asses the differences between the positive and E-cadherin negative group. Multivariate analysis was completed using the Cox proportional hazard regression model. Results E-cadherin immunoreactivity was not associated with FIGO stage, tumour grade, number of mitotic figures per 10 HPF, residual tumour volume or vascular invasion. Negative E-cadherin expression significantly predicted shorter OS ( p  
ISSN:0932-0067
1432-0711
DOI:10.1007/s00404-012-2684-9